Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

Cynthia L. Gay1,2, Joann D. Kuru1,2, Shane D. Falcinelli1,3, Joanna A. Warren1,3, Sarah A. Reifeis4, Jennifer L. Kirchner4, Katherine S. James1, Morgan G. Dewey1, Alyson Helms1,2, Brigitte Allard1, Erin Stuelke1, Alicia Gamble7, Ana Plachco7, Robert J. Gorelick5, Joseph J. Eron1,2,5, Michael Hudgens6, Carolina Garrido1,2, Nilu Goonetilleke1,3, Mark A. DeBenedette7, Irina Y. Tcherepanova7, Charles A. Nicolette7, Nancie M. Archin1,2 & David M. Margolis1,2,3,5*

Approaches to deplete persistent HIV infection are needed. We investigated the combined impact of the latency reversing agent vorinostat (VOR) and AGS-004, an autologous dendritic cell immunotherapeutic, on the HIV reservoir. HIV+, stably treated participants in whom resting CD4+ T cell-associated HIV RNA (rca-RNA) increased after VOR exposure ex vivo and in vivo received 4 doses of AGS-004 every 3 weeks, followed by VOR every 72 hours for 30 days, and then the cycle repeated. Change in VOR-responsive host gene expression, HIV-specific T cell responses, low-level HIV viremia, rca-RNA, and the frequency of resting CD4+ T-cell infection (RCI) was measured at baseline and after each cycle. No serious treatment-related adverse events were observed among five participants. As predicted, VOR-responsive host genes responded uniformly to VOR dosing. Following cycles of AGS-004 and VOR, rca-RNA decreased significantly in only two participants, with a significant decrease in SCA observed in one of these participants. However, unlike other cohorts dosed with AGS-004, no uniform increase in HIV-specific immune responses following vaccination was observed. Finally, no reproducible decline of RCI, defined as a decrease of >50%, was observed. AGS-004 and VOR were safe and well-tolerated, but no substantial impact on RCI was measured. In contrast to previous clinical data, AGS-004 did not induce HIV-specific immune responses greater than those measured at baseline. More efficacious antiviral immune interventions, perhaps paired with more effective latency reversal, must be developed to clear persistent HIV infection.

Life-long antiretroviral therapy (ART) is required to prevent rebound of viremia and return of disease, due to the persistence of long-lived viral reservoirs. Multiple mechanisms contribute to the complexity of latent and persistent HIV infection1. One of the best studied drivers of HIV latency is epigenetic control of integrated proviral DNA2. Lysine acetylation of histone tails by histone acetyl transferases is believed to result in neutralization of basic charges of core histones, leading to destabilization of DNA/histone interactions, increased accessibility of transcription factors to the HIV promoter (LTR), and transcription initiation. Deacetylation of lysine residues on histone tails by histone deacetylases (HDACs) is associated with decreased access of positive transcription factors to the LTR, and recruitment of histone-modifying and chromatin complexes implicated in transcriptional repression. HDAC inhibition antagonizes repression of HIV transcription, and has been investigated as a tool to

1University of North Carolina HIV Cure Center, UNC Institute of Global Health and Infectious Diseases, Chapel Hill, NC, United States. 2Department of Medicine, UNC Chapel Hill School of Medicine, Chapel Hill, NC, United States. 3Department of Microbiology and Immunology, UNC Chapel Hill School of Medicine, Chapel Hill, NC, United States. 4Department of Biostatistics, UNC Chapel Hill Gillings School of Public Health, Chapel Hill, NC, United States. 5Department of Epidemiology, UNC Chapel Hill Gillings School of Public Health, Chapel Hill, NC, United States. 6AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD, United States. 7Argos Therapeutics, Durham, North Carolina, USA. *email: dmargo@med.unc.edu
reverse HIV latency in humans\(^{3–7}\). While administration of HDAC inhibitors (HDACi) \(in vivo\) increased HIV transcription in each of these studies, a corresponding depletion of persistent infection has not been observed. Reversal of HIV latency at the transcriptional level may not deplete persistent infection because a) the effect is insufficiently broad or too transient to impact the reservoir, and/or b) immune mechanisms are of insufficient frequency or function to clear persistently infected cells following latency reversal, even in ART-treated individuals.

Exposure to the HDAC inhibitor vorinostat (VOR) induces HIV antigen expression sufficiently to allow viral clearance \(in vitro\)\(^{4,5}\). Four studies\(^{3,5–7}\) have demonstrated effective latency reversal \(in vivo\) at the level of cell-associated HIV RNA production following an initial dose of vorinostat (two studies), panobinostat, or romidepsin (one study each). Vorinostat has been shown to effectively and repeatedly reverse latency \(in vivo\) at the level of viral gene expression when given every 72 hours\(^4\). Therefore, we sought to determine whether romidepsin (one study each). Vorinostat has been shown to effectively and repeatedly reverse latency \(in vivo\) following an initial dose of vorinostat (two studies), panobinostat, or romidepsin (one study each). Vorinostat has been shown to effectively and repeatedly reverse latency \(in vivo\) at the level of viral gene expression when given every 72 hours\(^4\). Therefore, we sought to determine whether the addition of an immunotherapy to the administration of a latency reversing agent (LRA) would clear reactivated, formerly latently HIV-infected cells, leading to a decrease of the HIV reservoir. AGS-004 is a dendritic cell (DC)-based immunotherapy consisting of matured autologous DCs co-electroporated with \(in vitro\) transcribed ribonucleic acid (RNA) encoding autologous HIV antigens (gag, vpr, rev, and nef) plus synthetically derived cluster of differentiation 40 ligand (CD40L) RNA to achieve DC functionality\(^{10}\). This vaccine was reported to induce HIV-specific effector/memory CD8\(^+\) T-cell responses in HIV-infected individuals who had initiated ART during acute or chronic infection\(^{11–13}\).

In a prior open-label, single arm sub-study, AGS-004 was administered monthly to suppressed participants who started ART during acute HIV infection\(^11\). Participants demonstrating increased immune response after vaccination were eligible for analytic treatment interruption (ATI). The frequency of resting CD4\(^+\) T-cell infection (RCI) was measured by quantitative viral outgrowth assay. All participants underwent ATI with rebound viremia at a median of 29 days. AGS-00 before and after vaccination. induced a 2-fold increase from baseline in the number of multifunctional HIV-1 specific CD28\(^+\)/CD45RA\(^-\)/CCR7\(^-\)/CD45RA\(^-\)/CD8\(^+\) memory cytotoxic T-lymphocytes (CTLs) in all six participants, but did not permit sustained ART interruption. However, greater expansion of CD28\(^-\)/CCR7\(^-\)/CD45RA\(^-\)/CD8\(^+\) effector T cell responses correlated with a longer time to viral rebound. In this study we investigated the impact of VOR combined with AGS-004, on persistent HIV infection.

Results

Clinical outcome of VOR/AGS-004 combination. Twelve ART-treated, stably aviremic participants were initially enrolled in this step-wise study. Informed consent was obtained from all patients prior to study enrollment. Baseline ART was maintained throughout the study. Given the theoretical risks of vorinostat, and the low likelihood of clinical benefit in this study, we first confirmed \(ex vivo\) exposure to VOR resulted in a measurable increase in rca-RNA in the resting CD4\(^+\) T cells of participants from a donation provided after screening. Participants who had a measurable response to VOR \(ex vivo\) as measured by a significant increase in rca-RNA in resting CD4\(^+\) T cells progressed to receive a single 400 mg oral dose of VOR. If a significant increase in rca-RNA was measured, then response following two paired \(in vivo\) doses of VOR given at a 72 hr interval was assayed, to confirm that a 72 hr dosing interval was reproducibly effective at inducing rca-RNA \(in vivo\), as previously documented\(^1\). If a significant increase in rca-RNA was observed after the paired dose, then the participants went on to receive the combination of VOR and AGS-004.

Six of the 12 participants did not progress forward to receiving the single VOR dose either because of an absence of significant \(ex vivo\) response to VOR \((n=5\), data not shown\) or withdrawal of consent due to personal circumstances unrelated to the study \((n=1\). All 6 remaining participants received a single and then paired \(in vivo\) doses of VOR. We did not observe a significant increase in HIV RNA from the resting CD4\(^+\) T cells after administration of the \(in vivo\) paired VOR doses in one participant \((VV-05)\), and thus per protocol this participant did not progress to receive further study treatments \((data not shown)\).

Five participants, all male and white, received AGS-004 intradermal injections, and each dose consisted of 3 injections. The study was closed to accrual thereafter, as manufacturer of the AGS-004 vaccine could no longer produce vaccine for the study. The median age was 50 years \([range 29–62]\). Viremia in all participants was suppressed \(<50 \text{ copies/} \mu\text{L}\) for at least 5.1 years \([range 5.1–7.8]\) with a median baseline CD4\(^+\) count of 408 cells/\(\mu\)L \([range 382–746]\) and median CD4 nadir of 166 cells/\(\mu\)L \([range 81–403]\) at enrollment \((Table 1)\).

Participants received 4 consecutive doses of AGS-004 administered every 3 weeks over 12 weeks. Seven to ten days following the last dose of AGS-004, participants initiated ten consecutive doses of VOR at 72 hr intervals. The cycle of 4 doses of AGS-004 followed by 10 doses of VOR was repeated within 10 weeks of completing the first cycle, for a total of eight AGS-004 doses and 20 doses of VOR over approximately 10 months \((Fig. 1)\). Both AGS-004 and VOR were well tolerated by all participants with only mild AGS-004 site injection reactions, and possible VOR-associated mild, transient GI symptoms No symptoms approached grade I toxicity levels, and all resolved without treatment.

Expression of HDACi responsive genes confirm \(in vivo\) bioactivity of VOR. To confirm pharmacologic effect of VOR on cellular targets \(in vivo\), we evaluated the expression of several genes with predictable behavior in response to HDAC inhibition \(in vitro\). H1F0 and IRGM are upregulated and PHF15 and PRDM10 are downregulated in bulk PBMCs as well as resting CD4\(^+\) T cells following exposure to HDACi\(^14\). Across the 5 participants, we observed a pattern of gene modulation consistent with that described in \(ex vivo\) experiments and after a single \(in vivo\) VOR dose. H1F0 and IRGM were upregulated during q72 hour VOR dosing relative to baseline and returned to baseline levels after the cessation of dosing. Similarly, PHF15 and PRDM10 were downregulated during VOR dosing and returned to baseline expression levels after completion of dosing \((Fig. 2)\). There were a few departures from this trend in some participants where certain genes were not modulated or modulated in the opposite direction from predicted \((VV-01, PHF15; VV-02, H1F0 and IRGM)\); likely due to the multifactorial nature of transcriptional programming \(in vivo\) and variation associated with clinical sampling.
Overall, however, these data demonstrate that the pharmacological exposure to VOR in this study was sufficient to repeatedly alter host gene transcription over time.

**Minimal impact on the latent HIV reservoir by VOR and AGS-004.** It is hypothesized that therapies to disrupt virological latency, in combination with the use of vaccines or immunotherapies to assist in clearance of cells expressing HIV antigens, will be required to deplete the HIV reservoir. To that end we employed a dosing regimen of VOR that can repeatedly reverse latency in vivo of cells expressing HIV antigens, will be required to deplete the HIV reservoir. To that end we employed a dosing regimen of VOR that can repeatedly reverse latency in vivo together with an immunotherapeutic shown to generate HIV-specific immune responses. We used several approaches to assess the impact of combined immunotherapy and latency disruption on the HIV reservoir. rca-RNA was measured at baseline, and after the first and second cycle of combined therapy. Low-level viremia was measured by a single-copy assay (SCA) at baseline, after the first series of AGS-004 administrations, after the first and second cycle of VOR and AGS-004, and 7–10 days after the last dose of VOR. Finally, we measured the frequency of resting CD4+ T-cell infection by the quantitative viral outgrowth assay at the same time points as rca-RNA measurements. While the small sample size is a limitation of this study, we have previously identified a 6-fold decline in RCI measurement as a reliable threshold to assess the efficacy of anti-latency interventions in an individual, making it possible to capture a significant decrease in RCI even with a small sample size.

We observed quantitative increases in HIV Gag rca-RNA after the first and second therapy cycle in two of five participants (VV-04 and VV-06), and after the second therapy cycle in a third participant (VV-03), which could be due to VOR induction in the absence of sufficient cell clearance, or simply assay variance. However, in VV-01 and VV-02 we observed increases in rca-RNA after the first therapy cycle but a significant decrease in HIV Gag rca-RNA following the second round AGS-004 and VOR administration (Fig. 3). We observed a significant decrease in low-level viremia as measured by SCA (Table S1) for VV-02 (4.3 copies/ml at entry, and less than 0.5 copies/ml in three assays between visit 14 and 25), but viremia in other participants was either <1.0 or 1.1 copies/ml at all timepoints (VV-01, VV-03, VV-04), or intermittently detected from <1.0 to 84 copies/ml without a clear pattern (VV-06). However, the observed changes in rca-RNA and low-level viremia was not associated with a corresponding depletion of the replication competent reservoir as we failed to observe a significant decrease in RCI in all the participants (Table S2). Not unexpectedly, HIV DNA with resting CD4+ T cells was also stable (Fig. S1).

**Ex-vivo T cell immune reactivity to AGS-004.** T cell responses to HIV proteins were measured longitudinally by ex vivo IFN-γ ELISpot in each participant at time points before and after VOR and AGS-004 dosing. T cell responses were measured against both, proteins within the AGS-004 vaccine (Gag, Nef, Rev-Vpr), and others not in the vaccine (Env, Pol, Tat-Vif-Vpu). In VV-01, VV-02, VV-04, and VV-05, T cell responses to all HIV proteins, both those included or not included in the vaccine, were stable across time points. Less than a 1.5-fold change was observed from baseline in the frequency of HIV-specific T cell responses, whether total, or targeting proteins within or outside of the vaccine’s immunogens (Fig. S2). In VV-03, the summed HIV-specific T cell response increased ~1.5 fold over the course of the study. After the first cycle of AGS-004 dosing, summed HIV-specific T cell response increased from 1,434 SFU/10⁶ cells at visit 2 to 2,121 SFU/10⁶ cells at visit 16. The summed HIV-specific T cell response again increased after cycle 2 from 1,390 SFU/10⁶ cells at visit 20 to 2,250 SFU/10⁶ cells at visit 25. Importantly, the increases to the summed HIV-specific T cell response were driven by increases in T cells targeting HIV proteins found in the vaccine (Gag, Nef, Rev/Vpr subpool, 1093 SFU/10⁶ cells at visit 2 to 1,751 SFU/10⁶ cells at visit 16, and 1,105 SFU/10⁶ cells at visit 20 to 1,951 SFU/10⁶ cells at visit 25), and not to proteins outside of AGS-004 (Pol, Env, Tat/Vif/Vpu subpool, 341 SFU/10⁶ cells at visit 2 to 370 SFU/10⁶ cells at visit 16, and 284 SFU/10⁶ cells at visit 20 to 299 SFU/10⁶ cells at visit 25), suggesting the increases observed, while modest, were vaccine-induced (Fig. S2). In summary, as previously reported, VOR dosing had no effect on the HIV-specific T cell response. The AGS-004 vaccine induced T cell responses in ex vivo ELISpot in only 1 of 5 participants.

**Assessment of T cell and NK immune reactivity to AGS-004.** Previously, we reported in both acute and chronically infected HIV participants on ART therapy, an increase in the CD28⁺/CD45RA⁻ CD8⁺ memory CTL response after AGS-004 administration. Therefore, we assessed immune response in this way for participants receiving cycles of AGS-004 followed by VOR (Fig. 1). Baseline immune response was measured following VOR prior to AGS-004 dosing. Subsequent immune responses were measured at multiple timepoints during AGS-004 and VOR dosing, and at protocol completion.

### Table 1. Participant characteristics. *AHI: acute HIV Infection; CHI: chronic HIV infection. **At baseline. *Pre-Art.*

| PID | Race | Age (years)** | CD4 count (cells/ul) at enrollment | Nadir CD4* | Suppression (years) | ART Regimen** | Status at ART Initiation* |
|-----|------|--------------|-----------------------------------|------------|---------------------|--------------|-------------------------|
| VV-01 Caucasian | 49.6 | 542 | 403 | 8 | FTC, EFV, TDF | AHI |
| VV-02 Caucasian | 54.3 | 682 | 81 | 6.9 | RTV, TDF, FTC, NVP, IAPV | CHI |
| VV-03 Caucasian | 30.2 | 382 | 354 | 5.8 | TDF, FTC, ETR | CHI |
| VV-04 Caucasian | 54.3 | 408 | 157 | 6.1 | EVG, COBI, FTC, TDF | CHI |
| VV-06 Caucasian | 28.4 | 701 | 166 | 4.9 | DRV, RTV, TDF, FTC | CHI |
| Median | — | 49.6 | 542 | 166 | 6.1 | — | — |

Numbers of CD28⁺/CD45RA⁻ CD8⁺ memory CTL determined after *in vitro* stimulation with autologous DCs during the first and second cycles of AGS-004 and Vorinostat are shown in Fig. 4.

While increases in the...
numbers of CD28⁺/CD45RA⁻CD8⁺ memory CTL could be detected at various timepoints after the first or second cycle of AGS-004 and/or during VOR treatment, only participants VV-02 and VV-03 had significantly increased numbers of CD28⁺/CD45RA⁻CD8⁺ memory CTL which met the criteria for a positive immune response at visit 23. For participant VV-02 a positive response was recorded during both the first and second cycles of combined therapy. For VV-03 a positive response was recorded only during the second cycle of combined therapy. Individual functional marker responses within the total CD28⁺/CD45RA⁻CD8⁺ memory CTL immune response for each subject are shown (Fig. S3).

To further understand an AGS-004-induced immune response, we measured the total numbers of CD8⁺ T cells with any functional response at baseline and after each cycle of combined therapy, where sufficient cells were available for analysis (VV01-VV04). This analysis was undertaken to gauge the overall functional CD8⁺ T cells
response after ex vivo stimulation with autologous DCs. Overall there were statistically significant increases in CD8+ T-cells expressing granzyme B (Grb) in vitro for these participants (Fig. 5). The responses for participants VV-02 and VV-03 also became more multi-functional after cycle I and cycle II of combination therapy respectively with statistically significant increases in the numbers of CD8+ T cells secreting cytokines in combination with Grb.

Recent observations have reported that the in vivo administration of histone deacetylase inhibitors do not impair natural killer cell function in HIV+ individuals16. Therefore, we also measured NK cell responses after a six-day PBMC co-culture with or without autologous DCs. NK cells were defined using the CD3−CD56+CD16+ phenotype, with negative expression for both CXCR4 and CD45RA. After co-culture, activated NK cells (defined by expression of Grb) were present in all participants, and the percentage of activated NK cells increased following the first and second cycles of VOR in participants VV-02 and VV-03. When autologous DCs were added to co-cultures, the percentage of activated NK cells was also increased for participants VV-01 and VV-02 (Fig. 6). There was no significant increase in the percentage of activated NK cells determined for subject VV-04.

Viral Inhibition Assays. We have previously demonstrated the potential of various immunotherapies to augment HIV-specific effector responses, as measured by an in vitro autologous viral inhibition assay (VIA)17,18.

Figure 3. The effect of AGS-004 and VOR on HIV gag ca-RNA expression. Cell-associated HIV RNA was measured from pools of 24–36 million resting CD4+ T cells isolated from participants at baseline and after the first and second cycle of VOR + AGS-004. Wilcoxon Two-Sample Test was used to assess significant differences in HIV Gag caRNA between baseline and cycle I (A) and baseline and Cycle II (B) samples. Mean and SD is shown with corresponding p values. *Indicates a decrease in caRNA following cycle II of AGS-004 + VOR with corresponding p values.

Figure 4. Immune response after in vitro stimulation with autologous DCs. Number of CD28+CD45RA−CD8+ memory CTLs proliferating (BrdU positive) or expressing CD107α, GrB, IFN-γ, IL-2, or TNF-α were determined at the indicated time points during cycles of combination therapy. The numbers of cells/mL were determined by adding the numbers of cells/mL measured for each individual functional marker. Values were derived from the average and standard deviation of triplicate cultures.
To explore the possible correlations between in vivo responses in this pilot trial and the VIA, we assessed the antiviral activity of CD8⁺ T cells obtained after VOR and AGS-004 administration towards autologous participant CD4⁺ T cells super-infected with the laboratory strain JR-CSF or with HIV recovered and amplified from the individual's resting CD4⁺ T cells (autologous reservoir virus, ARV). CD8 T cells from all participants except VV-01 and VV-04 had little antiviral activity at baseline in this assay. We observed a trend towards an increase in the anti-viral capacity of CD8 T cells post VOR and AGS-004 treatment for VV-02 against JR-CSF, and for VV-01 and VV-04 against both JR-CSF and autologous reservoir virus (Figs. 7 and S4). However overall, no significant statistical differences were found between the antiviral activity of CD8⁺ T cells isolated before and after treatment for all participants.

**Discussion**

Currently antiretroviral therapy does not eliminate HIV-1 from latently-infected reservoirs19–21, and this remains the critical limitation to HIV eradication. Given a rapidly expanding number of HIV-infected individuals on lifelong ART worldwide, there is an urgent need for innovative therapies to control HIV-1 infection beyond what is currently possible with ART. We present the results of a pilot study combining a validated latency reversing agent with an immunotherapeutic shown to generate HIV-specific immune responses13.

Resting CD4⁺ lymphocytes comprise the largest and best characterized reservoir of HIV infection that persists despite ART22. Host cell molecular mechanisms that maintain the quiescence of HIV gene expression in infected resting CD4⁺ lymphocytes provide therapeutic targets within this largest and best-defined reservoir of HIV infection that persists despite ART. One of these latency mechanisms is the recruitment of histone deacetylases (HDACs) to the HIV long terminal repeat (LTR) promoter, mediating the formation of a repressive chromatin environment, a well-defined mechanism that inhibits LTR expression and HIV viral production. The relevance of this mechanism has been validated in numerous model systems and in the resting CD4⁺ T cells of ART-treated, aviremic individuals living with HIV2.

We and others have shown that HDAC inhibitors, such as VOR, can reverse HIV latency as measured by significant increase in cell-associated RNA expression12,7. In this study we administered VOR every 72 hours, as we had established this interval could repeatedly induce rca-RNA expression without significant clinical toxicity or immune dysfunction6,23,24.

In addition to latency-reversing agents, an enhanced and persistent HIV-1 specific immune response will be a required component of any cure strategy. Accordingly, this pilot study combined VOR administration with an HIV-1 specific immune therapy demonstrated activity in HIV-infected participants. The AGS-004 DC therapy is an individualized immunogen, and as generated from autologous PBMCs, addresses the inherent problem of HIV genetic diversity when using consensus HIV protein sequences as immunogens.

In a prior study, AGS-004 was safe and immunogenic in participants who initiated ART during acute HIV infection (AHI)11. DC therapy was administered to participants who initiated ART within 45 days of AHI and had HIV RNA < 50 c/ml for >6 months. Participants received 4 monthly doses of AGS-004 on ART. All six...
participants demonstrated positive immune responses defined as \( \geq 2 \)-fold increase from baseline in the number of CD28\(^+\)/CD45RA\(^-\)CD8\(^+\) memory CTL that display effector function to the antigens contained in AGS-004, Vpr, Nef, Gag, and Rev. These responses were durable over 12 weeks.

Other DC-based HIV vaccines have been developed and undergone clinical testing, these include autologous DCs transfected with gag/nef mRNA\(^25\), DCs loaded with autologous HIV infected apoptotic cells\(^26\), DCs pulsed with heat-inactivated whole HIV\(^27\), and DCs loaded with HIV lipopeptides\(^28\). In most of these clinical trials a slight improvement in HIV specific T cell responses was observed in terms of activation, breadth and frequency of functional T cells. Unfortunately, virologic outcomes were limited upon treatment interruption, with only modest decreases in the viral load set point. However, a correlation between immune function enhancement and viral load reduction was observed. Finally, because of the large inter-individual variation observed in the vaccine response, it has been proposed that factors such as the host genetics might play an important role in immuno-therapy outcomes\(^29,30\).

This pilot study in HIV-1-positive participants with durable viral suppression on stable ART sought to measure the potential of AGS-004 combined with Vorinostat to (1) stimulate expression of persistent proviral HIV from resting CD4\(^+\) T cells, (2) generate an HIV-specific immune response, and (3) when combined, clear persistent infection in HIV-infected participants in whom viral replication and spread is inhibited by uninterrupted ART.

12 participants enrolled in the study. One participant withdrew for personal reasons (relocation). Five were not advanced into the treatment steps of the protocol as no significant HIV RNA induction could be measured, most often due to low levels of RNA detected prior to cell treatment (<35 copies HIV RNA/million resting CD4 T cells). In only one participant, significant HIV RNA induction was measured \(ex vivo\), but was not observed after a single oral dose of VOR, and so the participant did not advance to further treatment. In all five participants, \(ex vivo\) induction of HIV RNA expression was paralleled by induction following both a single dose of VOR, and by the second of two doses of VOR separated by 72 hours. Following this observation, in our other ongoing studies we now screen only for \(in vivo\) response using paired dosing.

Overall, we found the combination of AGS-004 DC therapy and VOR to be safe and well-tolerated. No study-treatment related adverse events greater than Grade I were observed. The most common Grade I events were mild, self-resolving injection site reactions related to AGS-004.

Assays to assess histone acetylation as an \(in vivo\) biomarker of VOR pharmacologic activity are time-consuming and qualitative. We employed a PCR-based assay described by Maxwell \textit{et al.} (manuscript submitted) to assess the impact of VOR on host gene transcription, as a measure of host target engagement. The two host genes up-regulated (H1F0, IRGM) and two host genes that are down-regulated (PHF15 and PRDM10) were modulated as predicted upon repeated VOR dosing, suggesting that this assay will be useful in future clinical studies of HDAC inhibitors.
Unfortunately, these interventions had no measurable impact on the replication competent reservoir as measured by QVOA. We observed a significant decline of RCA-RNA in two of 5 participants after the second cycle of combination therapy. This could reflect depletion of cells producing full-length HIV RNA, a substantial proportion of which might not have been replication-competent and might therefore not contribute to a decline of RCI. As the frequency of cells expressing HIV RNA is much larger than that of cells capable of producing replication-competent HIV, a significant but modest decline of RCA-RNA may not be measurable as a significant decline of RCI. Alternatively, this decline could have been driven by another unknown cause of assay variation, as the RCA-RNA assay has not been extensively characterized in longitudinal studies. Given the small sample size and lack of a control group, we cannot completely dismissed that some of the increase or decrease in cRNA is perhaps due to longitudinal variation in cRNA expression. However, of note, VV-02 also had a decline in single-copy assay plasma viremia (SCA) from 4 copies/µl to <1.0 copies/µl at all post-AGS-004 timepoints, but SCA levels were too low to assess in 3 other participants and were unaffected in a fourth (VV-06).

There are several limitations to this work including as mentioned earlier, the small sample size and lack of a control group for this pilot study. Further, it is possible that more of an effect would have been seen with this combined immunotherapeutic strategy in participants who initiated ART earlier during acute infection or with higher baseline CD4 counts; three of five participants in this study had a CD4 nadir <200. However, one participant (VV-01) who started ART during acute infection did not demonstrate an increased response compared to those starting ART during established HIV infection.

Another factor that should be taken into consideration is that while we have evidence from an ex-vivo model system that VOR can induce sufficient antigen in resting CD4+ T cells from ART-treated participants to allow clearance of HIV infected cells by autologous CD8+ T cells, this finding has not yet been validated in vivo. Furthermore, while we can infer that there is sustained antigen presentation by AGS-004 DCs based on prolonged IL-12 secretion as a result of the CD40L RNA co-electroporated along with the HIV RNA, we cannot completely dismiss the possibility that suboptimal HIV antigen presentation by DCs in vivo contribute to the limited success of this study. Indeed, these questions can only be fully addressed in an in vivo study such as this one.

In this limited pilot study, absent clear findings in primary virological endpoints, we sought to probe for correlations between immune effects and the limited virological effects seen in VV-01 and VV-02. However, augmentation of the several immune responses measured were not consistently seen in these two participants. In summary, the serial administration of VOR appeared to reverse HIV latency in this selected cohort without...
clinical toxicity. However, no substantial augmentation of anti-HIV immune function was uniformly seen in this cohort of durably treated individuals living with HIV. Surprisingly, the induction and magnitude of HIV-specific immune responses by AGS-004 was marginal and inconsistent across participants, in contrast to what has been reported for AGS-004 elsewhere. The combination of AGS-004 DC therapy and VOR resulted in a decrease in cell-associated HIV RNA only in a minority of participants and had no substantial or uniform impact on the replication competent reservoir. Interestingly, depletion of the reservoir was not substantial even in the two participants with a measurable decrease in HIV rca-RNA, consistent with prior findings that most rca-RNA is replication defective. The need for the development of more potent latency reversal agents that robustly target the replication competent reservoir together with more efficacious immune interventions remains an important priority towards achieving an HIV cure.

**Materials and Methods**

**Human subjects.** This study was reviewed and approved by the University of North Carolina biomedical institutional review board, the NIAID Clinical Sciences Review Committee, and the Food and Drug Administration. This study, NCT02707900, was registered at Clinicaltrials.gov on 14 March 2016 and clinical trial monitoring performed by the NIAID. All research was performed in accordance with relevant US and institutional guidelines and regulations, and informed consent was obtained from all participants.

**Measurements of HDAC responsive genes.** PBMC were collected immediately prior to the first VOR dose, 4 hours after the 5th and 10th VOR dose, and 7–10 days after cessation of dosing. RNA was extracted using the Qiagen RNeasy kit (Germantown, MD), and was quantified using the NanoDrop1000 (Thermo Fischer Scientific, Waltham MA). Three reactions of cDNA per sample, each with an RNA input of 500 ng, were prepared using the Maxima cDNA synthesis kit with dsDNase according to the manufacturer's instructions (Thermo Fischer Scientific).

cDNA reactions were diluted 1:4 and subsequently used for qPCR in technical duplicates. 20 uL qPCR reactions consisted of 10 uL of QuantiTect Multiplex PCR NoROX Mastermix (Qiagen), 0.25 uL of AmpErase™ Uracil N-Glycosylase (Thermo Fischer Scientific), 2 uL of diluted cDNA, 400 nM or 1X primers, and 200 nM or 1X probes. Primers/probe sets for assessment of HDACi-modulated gene expression included previously validated primer/probe sets for H1F0, IRGM, and RPL27 from Integrated DNA Technologies or pre-designed 20X Taqman assays for PHF15 (Hs00959516) and PRDM10 (Hs00999748) from Thermo Fisher Scientific. qPCR cycling was conducted on the Bio-Rad C1000 Touch Thermal Cycler as follows: 50 °C × 2 min, 95 °C × 15 min, followed by 40 cycles of 94 °C × 1 min and 64 °C × 1 min. Cq values were determined using the automatic threshold analysis in the Bio-Rad CFX Maestro Software Version 1.1. Expression of HDACi-modulated host genes was assessed using the 2−ΔΔCt method. RPL27, a gene known to be non-responsive to HDACi stimulation, was used as a reference gene. For each round of vorinostat dosing in the study, fold change values were calculated relative to the baseline sample acquired immediately prior to dosing.

**Quantitative viral outgrowth assay (QVOA).** Lymphocytes were obtained by continuous-flow leukopheresis. Isolation of resting CD4+ T cells, recovery and quantification of replication competent virus was performed as described previously. Briefly, approximately 50 million resting CD4+ T cells were plated in replicate limiting dilutions of 2.5 million (18 cultures), 0.5 million (6 cultures) and 0.1 million (6 cultures) cells per well, activated with PHA (Remel, Lenexa, KS) and a 5-fold excess of allogeneic irradiated PBMCs from a seronegative donor, and 60 U/ml IL-2 for 24 hours. Cultures were washed and co-cultivated with CD8-depleted PBMCs collected from selected HIV seronegative donors screened for adequate CCR5 expression. Culture supernatants were harvested on days 15 and 19 and assayed for virus production by p24 antigen capture ELISA (ABL, Rockville MD). Cultures were scored as positive if p24 was detected at day 15 and was increased in concentration at day 19. The number of resting CD4+ T cells in infected units per million (IUPM) was estimated by a maximum likelihood method.

**Measurement of cell-associated HIV DNA, RNA and low-level viremia.** DNA was extracted from participant resting CD4 T cells using the Qiagen DNeasy® Blood & Tissue kit (Qiagen). Four replicates of 1 microgram of DNA was added to ddPCR™ Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA) with −RNA using the SuperScript® III First-Strand Synthesis SuperMix kit (Invitrogen, Carlsbad, CA) following the manufacturer's protocol. cDNA was synthesized in duplicate from DNase-treated, isolated PBMC were collected immediately prior to the first VOR dose, 4 hours after the 5th and 10th VOR dose, and 7–10 days after cessation of dosing. RNA was extracted using the Qiagen RNeasy kit (Germantown, MD), and was quantified using the NanoDrop1000 (Thermo Fischer Scientific, Waltham MA). Three reactions of cDNA per sample, each with an RNA input of 500 ng, were prepared using the Maxima cDNA synthesis kit with dsDNase according to the manufacturer's instructions (Thermo Fischer Scientific).

cDNA reactions were diluted 1:4 and subsequently used for qPCR in technical duplicates. 20 uL qPCR reactions consisted of 10 uL of QuantiTect Multiplex PCR NoROX Mastermix (Qiagen), 0.25 uL of AmpErase™ Uracil N-Glycosylase (Thermo Fischer Scientific), 2 uL of diluted cDNA, 400 nM or 1X primers, and 200 nM or 1X probes. Primers/probe sets for assessment of HDACi-modulated gene expression included previously validated primer/probe sets for H1F0, IRGM, and RPL27 from Integrated DNA Technologies or pre-designed 20X Taqman assays for PHF15 (Hs00959516) and PRDM10 (Hs00999748) from Thermo Fisher Scientific. qPCR cycling was conducted on the Bio-Rad C1000 Touch Thermal Cycler as follows: 50 °C × 2 min, 95 °C × 15 min, followed by 40 cycles of 94 °C × 1 min and 64 °C × 1 min. Cq values were determined using the automatic threshold analysis in the Bio-Rad CFX Maestro Software Version 1.1. Expression of HDACi-modulated host genes was assessed using the 2−ΔΔCt method. RPL27, a gene known to be non-responsive to HDACi stimulation, was used as a reference gene. For each round of vorinostat dosing in the study, fold change values were calculated relative to the baseline sample acquired immediately prior to dosing.

**Quantitative viral outgrowth assay (QVOA).** Lymphocytes were obtained by continuous-flow leukopheresis. Isolation of resting CD4+ T cells, recovery and quantification of replication competent virus was performed as described previously. Briefly, approximately 50 million resting CD4+ T cells were plated in replicate limiting dilutions of 2.5 million (18 cultures), 0.5 million (6 cultures) and 0.1 million (6 cultures) cells per well, activated with PHA (Remel, Lenexa, KS) and a 5-fold excess of allogeneic irradiated PBMCs from a seronegative donor, and 60 U/ml IL-2 for 24 hours. Cultures were washed and co-cultivated with CD8-depleted PBMCs collected from selected HIV seronegative donors screened for adequate CCR5 expression. Culture supernatants were harvested on days 15 and 19 and assayed for virus production by p24 antigen capture ELISA (ABL, Rockville MD). Cultures were scored as positive if p24 was detected at day 15 and was increased in concentration at day 19. The number of resting CD4+ T cells in infected units per million (IUPM) was estimated by a maximum likelihood method.

**Measurement of cell-associated HIV DNA, RNA and low-level viremia.** DNA was extracted from participant resting CD4 T cells using the Qiagen DNeasy® Blood & Tissue kit (Qiagen). Four replicates of 1 microgram of DNA was added to ddPCR™ Supermix for Probes (No dUTP) (Bio-Rad, Hercules, CA) with HindIII restriction enzyme for DNA digestion. Total HIV DNA was assessed using previously published primers and probe and standard ddPCR thermocycling conditions (Bio-Rad). Cell normalization was performed using two replicates of RPP30. Wells were merged together using the Bio-Rad Quantasoft Software and normalized to the baseline sample acquired immediately prior to dosing.

Changes induced in rca-RNA in vivo in response to VOR and AGS-004 dosing was measured as previously described with some minor modifications. Immediately following leukapheresis, resting CD4+ T-cells were isolated and plated at 1 million cells/well, pelleted, snap frozen, and stored at −80 °C. Total RNA was isolated from 36 replicates of 1 million resting cells using the MagnaSeq 96 Total RNA isolation kit (Life Technologies, Carlsbad, CA) following the manufacturer's protocol. cDNA was synthesized in duplicate from DNase-treated, isolated RNA using the SuperScript® III First-Strand Synthesis SuperMix kit (Invitrogen, Carlsbad, CA) according to the manufacturer's procedures. Reverse transcriptase was omitted from duplicate wells of each treatment condition and those wells served as controls for DNA contamination. Duplicate PCR amplification of duplicate cDNA was performed using the Bio-Rad FX96 Real-Time PCR machine and previously published primers and probe. A standard curve was generated for each PCR reaction as described previously. Results of the four PCR replicates representing each of the original 36 pools of RNA were averaged and the standard deviation determined for each condition. Statistical significance was determined as described under the statistical analysis subheading.
To measure low level viremia, HIV-1 from plasma was isolated by ultracentrifugation, the resulting pellet was extracted as described in Cline et al.42. HIV gag RNA copy numbers were assessed using the qPCR assay described in Somsouk et al.43. HIV-1 viral loads are reported as copies/mL of plasma.

**AGS-004 Manufacturing and dosing.** AGS-004 was manufactured at Argos Therapeutics, (Durham, NC) as previously described44. Monocytes were isolated from the leukocytes by elutriation and cultured in AIV-Media with 800 U/mL GM-CSF (Berlex Laboratories, Wayne NJ) and 1000 U/mL IL-4 (R&D Systems, Minneapolis MN) to generate immature DCs that are matured using 20 ng/mL TNF-α (R&D Systems)/1000 U/mL IFN-γ (InterMune, Brisbane CA)/1 μg/mL PGE, (Sigma, St. Louis MO). Mature DCs were electroporated with autologous pre-ART HIV RNA encoding Gag, Nef, Vpr and Rev and CD40L RNA using a post-maturation electroporation protocol described previously45. The final AGS-004 product was formulated as 1.4 × 10^7 DC/0.7 mL in 80% autologous plasma, 10% dextrose (50% w/v) (Hospira Lake Forest IL), and 10% DMSO (Sigma) and cryopreserved in liquid nitrogen vapor phase. Each patient was treated with an autologous dose of AGS-004 supplied as a cryopreserved, single dose vial containing a minimum of 6 million autologous matured dendritic cells (target 1.2 × 10^7 DCs) in 0.7 mL of suspension and is administered into a single lymph node basin as three intradermal injections of 0.2 mL each (0.6 mL total volume)46.

**Elispot assays.** 18-mer peptides overlapping by 10 amino acids were synthesized (SomaGenosys) to match the HIV Gag B consensus sequence and pooled by proteins in the AGS-004 vaccines Gag and Nef-Rev-Vpr and proteins not included in the vaccines, Pol, Env, Tat-Vif-Vpu. Peptide pools (quadruplicate) were pre- aliquotted into 96-well RB plates with media-only negative (6 replicates) and PHA positive control (duplicate) wells then stored at −80 °C. Cryopreserved PBMCs were thawed and rested 24 h before being added to ELISpot plates (Merck, Millipore) at 4 × 10^6 cells per well. All timepoints for each participant were run together. Antigens in the thawed plate were mixed with 1:1 with PBMCs in the ELISpot plate to a final concentration of 2 μg/mL and incubated for 18–20 hours at 37 °C, 5% CO₂. After incubation, cells were stained for viability using a viability dye (Invitrogen, Carlsbad CA) followed by surface staining with specific antibodies for detection of CD28, CD45RA, CD3, and CD8 expression. After surface staining, cells were fixed with 4% BD Cytofix and stored overnight in BSA staining buffer at 4 °C. The following day, the cells were permeabilized and DNase treated for 1 h at 37 °C using reagents included in the BDU staining kit (BD Biosciences). Intracellular staining for IFN-γ, TNF-α, IL-2, Grb and BrdU were performed. After staining, cells were washed and diluted in 500 μL BSA buffer and transferred to a BD TruCount Tube (BD Biosciences) for acquisition on a BD LSRII cytometer. 400,000–600,000 events were collected per sample. Number of cells/mL was calculated using the following formula: (number of cellular events × number of beads collected) × (bead concentration)/collected volume45.

The absolute number of viable CD8^+ CD3^+ T-cells positive for CD28 and negative for CD45RA and expressing any of the following six functional markers, IFN-γ, TNF-α, IL-2, Grb, CD107a, or the expression of the proliferation marker, BrdU were identified to the total HIV antigen payload. To determine the total number of functional CD28^+ CD45RA^− CD8^+ memory CTLs, the number of CD28^+ CD45RA^− CD8^+ memory CTLs having any functional activity were added together to determine absolute cells/mL. Per protocol, a positive immune response to AGS-004 was defined as ≥ 2-fold increase (plus 3 times STD) over baseline in the absolute number of CD28^+ CD45RA^− CD8^+ memory CTLs (cells/mL) exhibiting at least one effector function defined by the expression of IFN-γ, TNF-α, IL-2, Grb, CD107a, or proliferation. Baseline was defined as Visit 10 to designate the time prior to administration of AGS-004.

For detection of NK cells, frozen PBMCs were thawed and rested overnight and then cultured for 6 days with or without autologous DCs. After 6 days of culture cells were surface stained with antibodies to the following markers: CD3, CD4, CD8, CD25, CD45RA, CD16, CD56, and CXCR4 followed by staining for viability using Aqua Live/Dead Fixable Dye. Cells were washed and Transcription Factor Buffer set (BD Biosciences) was used to fix the cells. Following overnight storage at 4 °C in PBS stain buffer, cells were permeabilized by washing in Perm Wash buffer. Human IgG FC block was added to prevent non-specific antibody binding. After washing intracellular antibody to Grb was added. Cells were washed and acquired in BD True Count tubes for acquisition on a BD LSRII cytometer using FACS Diva software and 400,000–600,000 events were collected per sample. Data from acquired samples were analyzed using Flowjo software version 9.7.6 (Ashland OR). Insufficient PBMC were collected from participant VV-04 at visit 25 for analysis so visit 23 was used for an analysis after cycle II.
Viral inhibition assay. Viral inhibition assay was performed as previously described. CD8+ T-cells were isolated from PBMCs by positive selection (EasySep human CD8+ Selection Kit, Stem Cell, Vancouver, BC). CD8-depleted PBMCs were first activated with 4 μg/mL of PHA (Remel, Lenexa, KS) and 60 U/mL of IL-2, and then infected by inoculation at 1200 × 10^3 for 90 minutes with either JR-CSF or autologous reservoir virus (AR) at a MOI of 0.01. AR virus was obtained from pooled supernatants of replicate wells from outgrowth assays of resting CD4+ T-cells from each patient. Fifty-thousand (5 × 10^4) targets/well were co-cultured with CD8+ T-cells in triplicate at the indicated effector to target (E:T) ratio in 0.2 mL of IMDM media supplemented with 10% FBS, 1% Penicillin/Streptomycin and 5 μ/mL IL-2. P24 concentration in supernatant was assayed on day 6 by p24 ELISA Table of Contents (ABL, Rockville, MD).

Statistical analysis. The Wilcoxon Two-Sample test was used for statistical analysis of rca-RNA of pre- and post-VOR+ AGS-004 exposure groups. For viral inhibition assays, the Wilcoxon-Signed Rank test was used for statistical assessment of the effect of AGS-004 on the anti-viral function of CD8+ T-cells.

CD28+/CD45RA- CD8+ memory CTL responses at baseline and after AGS-004 administration were compared statistically using a 2-tailed Student t-TEST. Positive responses were determined by subtracting two times the total number of functional CD28+/CD45RA- CD8+ memory CTLs at baseline, from the total number of functional CD28+/CD45RA- CD8+ memory CTLs measured in response to in vitro stimulation with DC encoding the HIV antigens. Finally, the percentage of activated NK cells at baseline and after AGS-004 administration were compared statistically using a 2-tailed Student t test.

Data availability
All data is available in the main text or the supplementary materials.

Received: 11 July 2019; Accepted: 3 March 2020;
Published online: 20 March 2020

References
1. Mbonye, U. & Karn, J. The Molecular Basis for Human Immunodeficiency Virus Latency. Annu. Rev. Virol. 4, 261–285 (2017).
2. Turner, A. W. & Margolis, D. M. Chromatin Regulation and the Histone Code in HIV Latency. Yale J. Biol. Med. 90, 229–243 (2017).
3. Archin, N. M. et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487, 482–485 (2012).
4. Archin, N. M. et al. Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency. J. Clin. Invest. 127, 3126–3135 (2017).
5. Elliott, J. H. et al. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. PLoS Pathog. 10 (2014).
6. Rasmussen, T. A. et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV 1, 7004–70011 (2014).
7. Sogaard, O. S. et al. The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog. 11 (2015).
8. Garrido, C. et al. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo. J. Virol. 92 (2018).
9. Sung, J. A. et al. Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8+ T Cells. EbiolMedicine 23, 52–58 (2017).
10. Jacobson, J. et al. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J. Acquir. Immune Defic. Syndr. 72, 31–38 (2016).
11. DeBenedette, M. et al. In Conference on Retroviruses and Opportunistic Infections. Boston, MA. (2014).
12. Jenabian, M. A. et al. Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 64, 345–350 (2013).
13. Gay, C. L. et al. Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. AIDS Res. Hum. Retroviruses 34, 111–122 (2018).
14. Reardon, B. et al. Dose-responsive gene expression in suberyonanlide hydroxamic acid-treated resting CD4+ T cells. AIDS 29, 2235–2244 (2015).
15. Crooks, A. M. et al. Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. J. Infect. Dis. 15 (2015).
16. Garrido, C. et al. In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals. AIDS 33, 605–613 (2019).
17. Sung, J. A. et al. Expanded Cytotoxic T-cell Lymphocytes Target the Latent HIV Reservoir. J. Infect. Dis. 13 (2015).
18. Sung, J. A. et al. Dual-Affinity Re-Targeting proteins direct T-cell-mediated cytolysis of latently HIV-infected cells. J. Clin. Invest. 125, 4077–4090 (2015).
19. Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
20. Finzi, D. et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5, 512–517 (1999).
21. Chiu, T. W. et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 94, 13193–13197 (1997).
22. Archin, N. M., Sung, J. M., Garrido, C., Soriano-Sarabia, N. & Margolis, D. M. Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat. Rev. Microbiol. 12, 750–764 (2014).
23. Archin, N. M. et al. HIV-1 Expression Within Resting CD4+ T-Cells Following Multiple Doses of Vorinostat. J. Infect. Dis. 11, 11 (2014).
24. Clutton, G. et al. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function. Sci. Rep. 6, 30749 (2016).
25. Gandhi, R. T. et al. Immunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial. J. Acquir. Immune Defic. Syndr. 71, 246–253 (2016).
26. Macatangay, B. J. et al. Therapeutic Vaccination With Dendritic Cells Loaded With Autologous HIV Type 1-Infected Apoptotic Cells. J. Infect. Dis. 213, 1400–1409 (2016).
27. Garcia, E. et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5, 166ra162 (2013).
28. Levy, Y. et al. Dendritic cell-based therapeutic vaccine elicits polyfunctional HIV-specific T-cell immunity associated with control of viral load. *Eur. J. Immunol.* **44**, 2802–2810 (2014).

29. Moura, R. et al. Exome analysis of HIV patients submitted to dendritic cells therapeutic vaccine reveals an association of CNOT1 gene with response to the treatment. *J. Int. AIDS Soc.* **17**, 18938 (2014).

30. Reis, E. C. et al. Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy. *Hum. Vaccin. Immunother.* **14**, 1995–2002 (2018).

31. Pollack, R. A. et al. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T lymphocytes, which Shape the Proviral Landscape. *Cell Host Microbe.* **21**, 494–506.e494 (2017).

32. Ho, Y. C. et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. *Cell* **155**, 340–351 (2013).

33. Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. *Proc. Natl. Acad. Sci. USA* **115**, E2575–E2584 (2018).

34. Leth, S. et al. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy. *AIDS* **30**, 713–721 (2016).

35. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta Ct) Method. *Methods* **25**, 402–408 (2001).

36. Beliakova-Bethell, N. et al. Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells. *AIDS* **27**, 29–37 (2013).

37. Archin, N. M. et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. *AIDS* **22**, 1131–1135 (2008).

38. Trumble, I. M. et al. SLDAssay: A software package and web tool for analyzing limiting dilution assays. *J. Immunol. Methods* **450**, 10–16 (2017).

39. Myers, L. E., McQuay, L. J. & Hollinger, F. B. Dilution assay statistics. *AIDS* **30**, 713–721 (2016).

40. Malnati, M. S. et al. A universal real-time PCR assay for the quantification of group-M HIV-1 proviral load. *Nat. Med.* **12**, 1240–1248 (2008).

41. Israel-Ballerard, K. et al. TaqMan RT-PCR and VERSANT HIV-1 RNA 3.0 (bDNA) assay Quantification of HIV-1 RNA viral load in breast milk. *J. Clin. Virol.* **34**, 253–256 (2005).

42. Cline, A. N., Bess, J. W., Piatak, M. Jr. & Lifson, J. D. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. *J. Med. Primatol.* **34**, 303–312 (2005).

43. Somsouk, M. et al. The immunologic effects of mesalamine in treated HIV-infected individuals with incomplete CD4+ T cell recovery: a randomized crossover trial. *PloS One* **9**, e116306 (2014).

44. Goonetilleke, N. et al. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. *J. Virol.* **80**, 4717–4728 (2006).

45. Amin, A. et al. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. *J. Immunother Cancer* **3**, 14 (2015).

Acknowledgements

We thank DJ Hazuda and Merck Laboratories for the provision of vorinostat, and BJ Howell and JW Maxwell of Merck Laboratories for HDAC-responsive gene primers and methods. We are grateful for the expert procedural care provided by Y. Park and the UNC Blood Bank, and for clinical support from the staff of the UNC CTRC. Finally, we are grateful for the dedication of the participants who made this study possible. This study was supported by National Institutes of Health grants U01 AI 117844 and UM1 AI 126619 to D.M.M., National Institutes of Health grants UL1TR002489 to the UNC TRaCS Institute, and AI50410 to the UNC Center for AIDS Research. This work was supported in part with federal funds from the National Cancer Institute, National Institutes of Health, under contract no. HSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of any trade names, commercial products, or organizations imply endorsement by the U.S. government.

Author contributions

C.L.G., J.D.K., J.J.E., C.G., N.G., M.A.D., C.A.N., I.Y.T., N.M.A. and D.M.M. conceived and designed the studies. S.D.E., J.A.W., J.I.K., K.S.I., M.A.D., A.H., B.A., E.S., A.G., A.P., R.J.G., C.G., M.A.D., I.Y.T. and N.M.A. carried out the experiments. S.A.R. and M.H. assisted in analysis of the data. C.L.G., N.M.A. and D.M.M. wrote the manuscript with input from all authors.

Competing interests

J.J. Eron reports grants from Merck during the conduct of the study, personal fees from Merck, and personal fees from Gilead outside the submitted work. D.M. Margolis reports grants from N.I.H. during the conduct of the study, personal fees from Merck, and holds common stock in Gilead. C.L. Gay reports research grants from Viiv and Gilead during the conduct of this study. C.N. Nicolette, M. DeBenedette, I.Y. Tcherepanova, A. Gamble and A. Plachco were all fulltime employees of Argos Therapeutics at the time of the study.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-61878-3.

Correspondence and requests for materials should be addressed to D.M.M.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
